State of the Art ReviewCancer

On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

See allHide authors and affiliations

Science Translational Medicine  25 Mar 2015:
Vol. 7, Issue 280, pp. 280sr1
DOI: 10.1126/scitranslmed.3010274

You are currently viewing the abstract.

View Full Text

Abstract

The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.

View Full Text